RedHill Biopharma Ltd. has announced that it has received an extension from Nasdaq to comply with the minimum bid price requirement. This development is significant for the company as it now has until April 5, 2027, to regain compliance with the $1.00 per share requirement.
The extension was granted following a Notification Letter from the Listings Qualifications Department of The Nasdaq Stock Market LLC. Previously, the company was notified on April 8, 2026, that its American Depositary Shares (ADSs) had been trading below the minimum bid price for 30 consecutive business days.
RedHill Biopharma Ltd. is classified under the SIC code 2834, which pertains to pharmaceutical preparations. The company trades on the Nasdaq under the ticker symbol RDHL. The extension allows RedHill to continue its operations without immediate disruption, providing the company with additional time to explore strategies to meet the compliance requirements.
According to the filing, if the closing bid price of the ADSs reaches at least $1.00 per share for a minimum of 10 consecutive business days before the April deadline, Nasdaq will confirm compliance, and the matter will be closed. The company intends to monitor the closing bid price of its ADSs closely and will consider available options to regain compliance if necessary.
The notification from Nasdaq does not have an immediate effect on the listing or trading of the ADSs, which will continue to trade on The Nasdaq Capital Market. This situation may affect shareholders and investors, as compliance with listing requirements is crucial for maintaining market presence.
Looking ahead, the company is expected to continue its efforts to meet the compliance requirements before the expiration of the additional 180-day period. The filing does not specify what actions RedHill may take next to ensure compliance.